Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | NEK2 | P51955 | 1/20 | 0.57 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.55 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960296 | 0.86 | CA2 (0.53) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL29643330 | 0.86 | CA2 (0.53) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL8990307 | 0.85 | CHEK1 (0.73) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL29919884 | 0.85 | CHEK1 (0.73) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL4978920 | 0.81 | PKM (0.39) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL30710586 | 0.77 | RXFP1 (0.48) | PKMPOLBMAPTLMNAHTT | |
| SCHEMBL198796 | 0.77 | RXFP1 (0.48) | PKMPOLBMAPTLMNAHTT | |
| SCHEMBL29429114 | 0.77 | RXFP1 (0.48) | PKMPOLBMAPTLMNAHTT | |
| SCHEMBL3292189 | 0.77 | PKM (0.38) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL16846550 | 0.75 | CHEK1 (0.41) | CHEK1NEK2LIMK1DYRK1ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9796725-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170217968-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9663525-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160244455-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-9290500-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2814791-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140088096-A9 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2013123169-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130217682-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-7767817-B2 | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-03 | — | — | US | disclosed |
| CN-101599556-A | A kind of electrolysis additive and contain the electrolyte and the lithium ion battery of this additive | BYD CO LTD (CN) | 2009-12-09 | — | — | CN | disclosed |
| CN-101291665-A | Naphthyl derivatives as inhibitors of beta-amyloid aggregation | SIGMA TAU IND FARMACEUTI (IT) | 2008-10-22 | — | — | CN | disclosed |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-16 | — | — | US | disclosed |
| EP-1937243-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-07-02 | — | — | EP | disclosed |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-29 | — | — | US | disclosed |
| WO-2007045593-A2 | NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-26 | — | — | WO | disclosed |
| WO-2005024416-A1 | WATER SOLUBLE BORONIC ACID FLUORESCENT REPORTER COMPOUNDS AND METHODS OF USE THEREOF | WANG BINGHE (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | UBA1, UBXN1, UBE2E1 | CHEK1 2369/4885NEK2 1540/4885LIMK1 1127/4885 |
| US-20070274922-A1 | Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof | GUSB, BLVRB, BCL6 | CHEK1 3082/4885NEK2 2822/4885LIMK1 2468/4885 |
| US-20130217682-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | CHEK1 2369/4885NEK2 1540/4885LIMK1 1127/4885 |
| US-20160244455-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | CHEK1 2369/4885NEK2 1540/4885LIMK1 1127/4885 |
| US-20140088096-A9 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | CHEK1 2369/4885NEK2 1540/4885LIMK1 1127/4885 |
| US-20080255232-A1 | Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation | APP, BACE1, SNCA | CHEK1 4299/4885NEK2 984/4885LIMK1 1955/4885 |
| US-20170217968-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | CHEK1 2369/4885NEK2 1540/4885LIMK1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.